drugset / Trial / NCT00005039

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

NCT00005039

Phase 2 Terminated 86 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells

Timeline

Start
2000-01
Primary completion
2007-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant fowlpox-prostate specific antigen vaccine Vaccine Intramuscular
Subject recombinant vaccinia prostate-specific antigen vaccine Vaccine Other